Homocysteine-induced thrombosis

British Journal of Biomedical Science

Volumn 61, Issue 1, 2004, Pages 40-47

  Edirisinghe, S P ^a  

^a Hillingdon Hospital NHS Trust   (United Kingdom)

Author keywords

Homocysteine; Thrombosis

Indexed keywords

HOMOCYSTEINE;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; HOMOCYSTINURIA; HUMAN; ISCHEMIC HEART DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

EID: 1842483147     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2004.11732643     Document Type: Review

References (53)

1. Du Vigneaud VE. A trail of research in sulfur chemistry. Ithaca, NY: Cornell University Press, 1952.
2. McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Atherosclerosis 1975; 22: 215-27.
3. Harker LA, Harlan JM and Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circ Res 1983; 53: 731-9.
4. McCully KS. Homocysteine theory of arteriosclerosis: development and current status. In: Gotto AM Jr, Paoletti R, eds. Atherosclerosis reviews (Vol 11). New York: Raven Press, 1983: 157-246.
5. McCully KS. The biomedical significance of homocysteine. J Sci Expl 2001; 15: 5-20.
6. Verhoef P, Kok FJ, Kruyssen DA et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscl Thromb Vasc Biol 1997; 17: 989-95.
7. Ridker PM, Manson JE, Buring JE, Shih J, Matias M, Hennekens CH. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 1999; 281: 1817-21.
8. Langman LJ, Ray JG, Evrovski J, Yeo E, Cole DEC. Hyperhomocysteinemia and the increased risk of venous thromboembolism - more evidence from a case-control study. Arch Intern Med 2000; 160: 961-4.
9. Wall RT, Rubenstein MD, Cooper SL. Studies on the cellular basis of atheroscelerosis - the effects of atheroscelerosis risk-factors on platelets and the vascular endothelium. Diabetes 1981; 30: 39-43.
10. Brattstrom L, Tengborn L, Lagerstedt C, Israelsson B, Hultberg B. Plasma homocysteine in venous thromboembolism. Haemostasis 1991; 21: 51-7.
11. Kang SS Wong PWK, Malinow MR. Hyperhomocysteinemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992; 12: 279-98.
12. Mckinley MC. Nutritional aspects and possible pathological mechanisms of hyperhomocysteinemia: an independent risk factor for vascular desease. Proc Nutr Soc 2000; 59: 221-37.
13. Cattaneo M. Hyperhomocysteinemia and thrombosis. Lipids 2001; 36: 513-26.
14. Den Heijer M, Keijzer MBAJ. Hyperhomocysteinemia as a risk factor for venous thrombosis. Clin Chem Lab Med 2001; 39: 710-3.
15. Naruszewicz M, Mirkiewicz E, Olszewski AJ, McCully KS. Thiolation of low-density lipoprotein by homocysteine thiolactone causes increased aggreation and interaction with cultured macrophages. Nutr Metab Cardiovasc Dis 1994; 4: 70-7.
16. McCully KS. The chemical pathology of homocysteine. II. Carcinogenesis and homocysteine thiolactone metabolism. Ann Clin Lab Sci 1994; 24: 27-59.
17. Stabler SP, Steegborn C, Whal MC et al. Elevated plasma total homocysteine in severe methionine adenosyltransferase I/II deficiency. Metabolism 2002; 51: 981-8.
18. Poirier LA. The effects of diet, genetics and chemicals on toxicity and aberrant DNA methylation: an introduction. J Nutr 2002; 132: 2336S-2339S.
19. Zappacosta A, Moordete A, Persichilli S et al. Is homocysteine a pro-oxidant. Free Radic Res 2001; 35: 499-505.
20. Ragone R. Homocysteine solubility and vascular desease. FASEB J 2002; 16: 401-4.
21. Stanger O, Weger M, Renner W, Konetschny R. Vascular dysfunction in hyperhomocysteinemia. Implication for atherothrombotic disease. Clin Chem Lab Med 2001; 39: 725-33.
22. Willems FF, Aengevaeren WRM, Boers GHG, Blom HJ, Verheugt FWA. Coronary endothelial function in hyperhomocysteinemia: improvement after treatment with folic acid and cobalamin in patients with coronary artery disease. J Am Coll Cardiol 2002; 40: 766-72.
23. Li NJ, Yi FX, Rute E, Zhang DX, Slocum GR, Zou AP. Effects of homocysteine on intracellular nitric oxide and superoxide levels in the renal arterial endothelium. Am J Physiol 2002; 283: H1237-H1243.
24. Li JX, Zhang YG, Yao XH, Zhang BW, Du JB, Tang CS. Effect of homocysteine on the L-arginine/nitric oxide synthase/nitric oxide pathway in human platelets. Heart Vessels 2002; 16: 46-50.
25. Clarenbach P, Wessendorf T. Sleep and stroke. Rev Neurol (Paris) 2001; 157: 546-52.
26. Signorello MG, Pascale R, Leoncini G. Effect of homocysteine on arachidonic and release in human platelets. Eur J Clin Invest 2002; 32: 279-84.
27. Queffeulou G, Michel C, Vrtovsnik F, Philit JB, Dupuis E, Mignon F. Hyperhomocysteinemia, low folate status, homozygous C-677 T mutation of the methylene tetrahydrofolate reductase and renal arterial thrombosis. Clin Nephrol 2002; 57: 158-62.
28. Morelli VM, Lourenco DM, D'Almeida V et al. Hyperhomocysteinemia increases the risk of venous thrombosis independent of the C677T mutation of the methylenetetrahydrofolate reductase gene in selected Brazilian patients. Blood Coagul Fibrinolysis 2002; 13: 271-5.
29. Martinelli I, Bucciarelli P, Zighetti ML, Cafro A, Mannuccci PM. Low risk of thrombosis in family members of patients with hyperhomocysteinemia. Br J Haematol 2002; 117: 709-11.
30. Lin JS, Shen MC, Cheug WC et al. Age, sex and vitamin status affect plasma level of homocysteine, but hyperhomocysteinaemia is possibly not an important risk factor for venous thrombophilia in Taiwanese Chinese. Br J Haematol 2002; 117: 159-63.
31. Tan NCK, Venketasubramanian N, Saw SM, Tjia HTL. Hyperhomocysteinemia and risk of ischemic stroke among young Asian adults. Stroke 2002; 33: 1956-62.
32. Cappuccio FP, Bell R, Perry IJ et al. Homocysteine levels in men and women of different ethnic and cultural background living in England. Atherosclerosis 2002; 164: 95-102.
33. Simpore J, Pigatelli S, Meli C, Malaguarnera M, Chillemi R, Muscumeci S. Nutritional and racial determinants of the increase in plasma homocysteine levels after methionine loading. Curr Ther Res 2002; 63: 459-73.
34. Murphy MM, Scott JM, McPartlin JM, Fernande-Ballart JD. The pregnancy-related decrease in fasting plasma homocysteine is not explained by folic acid supplementation, hemodilution or a decrease in albumin in a longitudinal study. Am J Clin Nutr 2002; 76: 614-9.
35. Nurk E, Tell GS, Vollset SE, Nygard O, Refsum H, Ueland PM. Plasma total homocysteine and hospitalization for cardiovascular disease - the Hordaland Homocysteine Study. Arch Intern Med 2002; 162: 1374-81.
36. Streifler JY, Rosenberg-Chetrit A, Eskaraev R et al. Cerebrovascular events in patients with significant stenosis of the carotid artery are associated with hyperhomocysteinemia and platelet antigen-1 (Leu33Pro) polymorphism. Stroke 2001; 32: 2753-8.
37. Nowak-Gottl U, Kosch A, Schlegel N, Salem M, Manco-Johnson M. Thromboembolism in children. Curr Opin Haematol 2002; 9: 448-53.
38. Nikfardjam M, Graf S, Hornykewycz S et al. Homocysteine plasma levels in young patients with coronary artery disease - relation to history of acute myocardial infarction and anatomical extent of disease. Thromb Res 2001; 103: S35-S39.
39. Herrmann W. The importance of hyperhomocysteinaemia as a risk factor for diseases: an overview. Clin Chem Lab Med 2001; 39: 666-74.
40. Malinow MR, Bostom AG, Krauss RM. Homocysteine, diet and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999; 99: 178-82.
41. Zhou J, Moller J, Danielsen CC et al. Dietary supplementation with methionine and homocysteine promotes early atherosclerosis but not plaque rupture in apoE-deficient mice. Arterioscl Thromb Vasc Biol 2001; 21: 1470-6.
42. Klerk M, Verhoef P, Verbruggen B et al. Effect of homocysteine reduction by B vitamin supplementation on markers of clotting activation. Thromb Haemost 2002; 88: 230-5.
43. Robinson K, Mayer EL, Miller DP et al. Hyperhomocysteinemia and low pyridoxal-phosphate-common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92: 2825-30.
44. Andrreotti F, Burzotta F, Mazza A, Manzoli A, Robinson K, Maseri A. Homocysteine and arterial occlusive disease: a concise review. Cardiologia 1999; 44: 341-5.
45. Shimakawa T, Nieto FJ, Malinow MR, Chambless LE, Schreiner PJ, Szklo M. Vitamin intake: a possible determinant of plasma homocysteine among middle-aged adults. Ann Epidemiol 1997; 7: 285-93.
46. De Souza C, Keebler M, McNamara DB, Fonseca V. Drugs affecting homocysteine metabolism - impact on cardiovascular risk Drugs 2002; 62: 605-16.
47. James SJ, Melnyk S, Pogribna M, Pogribny IP, Candill MA. Elevation in S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr 2002; 132: 2361S-2366S.
48. Stover PJ, Garza C. Bringing individuality to public health recommendations. J Nutr 2002; 132: 2476S-2480S.
49. Legendre C, Causse E, Chaput E, Salvayre R, Pineau T, Edgar AD. Fenofibrate induces a selective increase of protein-bound homocysteine in rodents: a PPAR alpha-mediated effect. Biochem Biophys Res Commun 2002; 295: 1052-6.
50. Rasmussen K, Moller J. Total homocysteine measurement in clinical practice. Ann Clin Biochem 2000; 37: 627-48.
51. Ducros V, Candito M, Causse E et al. Comparision of plasma total homocysteine determination in 9 French hospital laboratories by using 6 different methods. Ann Biol Clin (Paris) 2002; 60: 421-8.
52. Clarke R, Stansbie D. Assessment of homocysteine as a cardiovascular risk factor in clinical practice. Ann Clin Biochem 2001; 38: 624-32.
53. Nexo E, Engbaek F, Ueland PM et al. Evaluation on novel assays in clinical chemistry: quantification of plasma total homocysteine. Clin Chem 2000; 46: 1150-6.